Bio-Rad Laboratories, Inc. filings document operating results, governance, capital structure, and material events for a Delaware company that develops, manufactures, and markets life science research and clinical diagnostics products.
Form 8-K reports furnish quarterly and annual earnings releases, supplemental earnings materials, Regulation FD presentations, Droplet Digital PCR product-portfolio disclosures, and updates related to the company’s investment in Sartorius AG. Proxy materials cover board elections, executive compensation, shareholder voting matters, governance practices, and Class A and Class B common stock disclosures.
Bio-Rad Laboratories EVP and Chief Financial Officer Roop Kalyan Lakkaraju reported routine equity compensation activity. On April 24, 2026, 1,078 shares of Class A common stock were acquired upon vesting of restricted stock units and converted from derivative form.
To cover tax obligations, 420 shares were disposed of through a tax-withholding transaction at $287.84 per share, leaving 2,563.895 Class A shares held directly. The filing also notes 2,156 restricted stock units remaining outstanding and references a prior 4,311-unit RSU grant vesting in four annual installments.
BIO-RAD LABORATORIES, INC. executive vice president and general counsel Courtney C. Enloe reported routine equity compensation activity. On April 24, she acquired 186 shares of Bio-Rad Class A common stock upon the vesting and conversion of restricted stock units, then had 77 shares withheld to cover tax obligations. These transactions increased her direct holdings to 826.777 Class A shares and reduced her restricted stock unit balance to 372 units from an original 744-unit grant scheduled to vest in four equal annual installments.
Bio-Rad Laboratories reported results of its April 21, 2026 annual meeting. Stockholders approved an amended 2017 Incentive Award Plan that increases the shares of common stock reserved for issuance by 335,000 and extends the plan’s expiration to March 18, 2036.
All nominated directors were elected by the required majorities, KPMG LLP was ratified as independent auditor for the year ending December 31, 2026, and executive compensation received majority support in a non-binding advisory vote. A stockholder proposal regarding the company’s dual class capital structure did not receive the required majority approval.
Hinckley Greg K reported acquisition or exercise transactions in this Form 4 filing.
Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through routine equity compensation. On April 21, 2026, 407 restricted stock units vested and were settled into 407 shares of Bio-Rad Class A common stock. Following this settlement, Hinckley directly held 1,215 shares of Class A common stock.
On the same date, he received a new grant of 369 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. These units will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Bio-Rad Laboratories director Melinda Litherland reported routine equity compensation activity. She exercised 407 restricted stock units into 407 shares of Bio-Rad Class A common stock, bringing her direct common stock holdings to 715 shares.
On the same date, she received a new grant of 369 restricted stock units, each representing a right to one share of Class A common stock. These new units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of stockholders, aligning her compensation with future company performance and governance milestones.
Bio-Rad Laboratories director Jeffrey L. Edwards exercised restricted stock units into Bio-Rad Class A common shares and received a new equity award. He acquired 407 shares of Bio-Rad A Common Stock upon vesting of restricted stock units, bringing his direct holdings to 715 shares.
At the same time, 407 Restricted Stock Units were fully converted, leaving no remaining units from that grant. Edwards was also granted 369 new Restricted Stock Units, each representing a contingent right to receive one share of Bio-Rad Class A common stock, vesting 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
BIO-RAD LABORATORIES, INC. director Arnold A. Pinkston reported routine equity compensation activity. He acquired 407 shares of Bio-Rad Class A common stock upon vesting of restricted stock units, bringing his direct common stock holdings to 715 shares after the transaction.
The filing also shows 407 restricted stock units were fully settled, reducing that RSU position to zero. In addition, he received a new grant of 369 restricted stock units, each representing one share of Class A common stock, which will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
The Vanguard Group filed an amended Schedule 13G reporting that it currently beneficially owns 0 shares (0%) of Bio-Rad Laboratories Inc. The filing explains that on January 12, 2026 Vanguard completed an internal realignment and began reporting certain subsidiaries' holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Bio-Rad Laboratories is asking stockholders to vote at its 2026 annual meeting on director elections, auditor ratification, executive pay, an amended long‑term incentive plan, and a stockholder proposal on its dual‑class structure. The meeting will be held on April 21, 2026 at company headquarters in Hercules, California.
Holders of Class A and Class B shares vote separately to elect two and four directors, respectively, while most other items are decided by a majority of combined voting power present. The board recommends voting for all company proposals, including the advisory say‑on‑pay and the amended 2017 Incentive Award Plan, and against the stockholder proposal seeking changes to the dual‑class capital structure.
The amended equity plan would add to the share reserve and extend the plan’s term to March 18, 2036, with features such as minimum one‑year vesting (with limited exceptions), clawback applicability, no dividends on unvested awards, and a per‑director annual award cap. KPMG LLP is proposed to continue as independent auditor, with 2025 audit fees of $6,192,000 and other 2025 fees of $244,000.